Polygenic risk scores Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines polygenic risk scores, which combine the effect of many common genetic variants into a single estimate of the risk of a disease such as coronary artery disease, breast cancer or type 2 diabetes. It tests how fast clinical grade scores move from research and consumer products into cardiology, cancer screening and preventive care, and which participants capture value among score developers, laboratories, genotyping suppliers, health systems and insurers.

The largest clinical implementation study sets the benchmark. The eMERGE network, funded by the US National Human Genome Research Institute, launched clinical reporting in July 2022 for ten common conditions, with plans to assess 5,000 children and 20,000 adults of diverse ancestry. In the first 2,500 participants, 20.6% had a high risk score for at least one condition and 2.6% for two, and odds ratios for the high risk groups ranged from about 2 to 7. The conclusion is that a meaningful share of people receive an actionable result, and the scores identify risk groups that differ several fold in disease risk.

Accuracy of the laboratory method is high, and accuracy across ancestries is the open question. Scores calculated on a genotyping array matched whole genome sequencing at 93% for breast cancer and up to 99.5% for type 1 diabetes and obesity, with full repeatability, while validation required discrimination in at least two to four ancestry groups. The conclusion is that the laboratory side is ready for clinical use, and the evidence from diverse populations decides which scores can be offered widely.

Commercial products reached clinics in 2022. Allelica launched ancestry specific scores for coronary artery disease, breast cancer, prostate cancer, type 2 diabetes and Alzheimer disease as a laboratory developed test in September 2022, with Mass General Brigham offering the test through its preventive genomics clinic, and Genomics plc and Myriad Genetics also supply scores through health systems. The conclusion is that the first buyers are preventive clinics and health systems, and growth depends on whether guidelines and insurers accept the scores for decisions on statins and screening.

Trials are now testing whether disclosure changes care. Allelica is working with Mass General Brigham and the US Department of Veterans Affairs on a cardiovascular study of whether giving patients a risk score improves statin use and reduces adverse events, and has licensed the BOADICEA breast cancer model from the University of Cambridge to combine with its scores. The conclusion is that evidence of better outcomes and integrated models, not new scores alone, will decide acceptance in cardiology and cancer screening.

The brief treats polygenic risk scores as an emerging category with a ten year horizon to 2036. It identifies which applications, regions and operators scale first and what each means for score developers, laboratories, genotyping suppliers, health systems and insurers. It is a focused 102-page decision brief that presents an indicative trajectory rather than a segmented market model.

A polygenic risk score adds up the small effects of thousands to millions of genetic variants to estimate how a person compares with others in risk of a disease.

Scores are calculated from a low cost genotyping array, with imputation to fill in untyped variants and calibration for ancestry, and are reported as high risk or not high risk for each condition.

Integrated models combine scores with family history, rare variants such as BRCA genes and clinical factors, for example by feeding a score into the BOADICEA breast cancer model.

Uses are identifying people at high risk of coronary disease, breast and prostate cancer, diabetes and other conditions, so that prevention or screening starts earlier, each under laboratory test rules.

The limits are lower accuracy in non-European ancestries, lack of guidelines and coverage, limited evidence of changes in outcomes, and challenges in communicating risk. The period turns on whether outcome studies lead guidelines and insurers to support scores.

The polygenic risk score market, covering clinical risk score tests, genotyping consumables, laboratory services and interpretation software used in preventive care, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 1.38–2.76 billion by 2036, at a CAGR of 30%.

The 2026 base rests on clinical risk score tests, genotyping consumables, laboratory services and software sold to health systems, preventive clinics and direct to consumer channels. Growth then follows guideline recommendations, insurer coverage and integration in cardiology and cancer screening.

The forecast is sensitive to guideline decisions, evidence of outcome benefit and ancestry coverage. Regionally, North America leads on implementation studies and laboratories, Europe on score developers and national health system interest, and Asia-Pacific on large cohorts and genotyping suppliers.

Scenarios.

The base case assumes implementation studies show benefit and guidelines recommend scores for selected decisions by 2031, giving the inflection in 2033. An accelerated case assumes early positive outcome studies and insurer coverage, bringing the inflection to 2031 and lifting the 2036 value to the top of the range. A delayed case assumes concerns over accuracy across ancestries and no guideline support, holding growth at the bottom of the range.

Growth drivers

• Clinical implementation programmes.
• Integration in cardiology and cancer screening.
• Low cost genotyping.
• Consumer and health system demand.

Enablers

• Research funding and consortium programmes.
• Health system and laboratory partnerships.
• Large genetic cohorts with ancestry diverse data.
• Electronic health record integration.

Restraints and barriers

• Lower accuracy in non-European ancestries.
• Lack of guidelines and coverage.
• Limited evidence of clinical utility.
• Ethical and communication challenges.

The direction of polygenic risk scores is set by the need to identify high risk people before disease, regulation, guidelines and ethics, better scores and ancestry coverage, partnering among health systems, insurers and developers, and genotyping cost and data access.

The key participants in polygenic risk scores include Allelica, Inc., Genomics plc, MyOme, Inc., Myriad Genetics, Inc., Tempus AI, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, GeneDx Holdings Corp., Fulgent Genetics, Inc., Color Health, Inc., F. Hoffmann-La Roche Ltd, Eurofins Scientific SE, BGI Genomics Co., Ltd., Natera, Inc., ProPhase Labs, Inc., Regeneron Pharmaceuticals, Inc., SOPHiA GENETICS SA, Agilent Technologies, Inc., eMERGE Network, Broad Institute, Mass General Brigham, National Human Genome Research Institute, National Institutes of Health, U.S. Department of Veterans Affairs, University of Cambridge, Cleveland Clinic, Mayo Clinic, NHS England, Genomics England, American College of Medical Genetics and Genomics, American Heart Association, American College of Cardiology, UnitedHealth Group Incorporated, Centers for Medicare & Medicaid Services, U.S. Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, European Commission and Clinical and Laboratory Standards Institute.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as polygenic risk scores mature.

Allelica and Genomics plc lead among dedicated score developers, Myriad Genetics and MyOme extend scores into their genetic testing and risk models, and Illumina and Thermo Fisher Scientific supply genotyping and sequencing. Laboratory Corporation of America Holdings, Quest Diagnostics and Color Health provide the clinical channel. Competitive intensity is moderate in 2026 and rises as guidelines emerge.

Where value migrates.

In 2026 value sits with score developers that have clinical partners and multi-ancestry validation, because buyers are preventive clinics and health systems that pay for a report. By 2031 it moves toward companies named in guidelines and covered by insurers, because coverage turns a test into a routine service. By 2036 it settles in integrated preventive care platforms that combine scores, family history, rare variants and clinical data. Margins hold for developers with validated scores and health system contracts and narrow for stand-alone scores sold directly.

The signals converge on clinical implementation and growing products. A ten condition implementation study found a high risk score in 20.6% of the first 2,500 participants, commercial multi-ancestry scores reached clinics, and trials are testing effects on statin use. Each signal supports growth, and accuracy across ancestries, missing guidelines and limited outcome evidence limit the pace.

Structural limits show where progress could slow: lower accuracy in non-European ancestries, lack of guidelines and coverage, limited evidence of clinical utility, and ethical and communication challenges. The brief therefore tracks four indicators: guideline recommendations, implementation study results, insurer coverage, and people tested.

Coronary disease and breast cancer first, then diabetes and prostate cancer, then wider preventive care are the expected order of adoption.